Uniqure’s CEO dined with investors. Here’s what he said

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.

This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox.

Uniqure CEO Matt Kapusta told a group of investors at a private dinner on Tuesday that the Trump White House “doesn’t like all the drama” inside the Food and Drug Administration, just a week after the company said the agency had upended its plan to seek a speedy approval for a gene therapy to treat Huntington’s disease. 

The decision to appoint longtime cancer chief Rick Pazdur as the agency’s top drug regulator — a job offer Pazdur initially declined but then accepted — is a sign of how seriously the administration is taking the FDA dysfunction, Kapusta also said.